Lastly, the regulatory effects of SV on cav1 and TP53, important biomarkers for initiating arrhythmia in the atherosclerosis pathway, may be a key factor in reducing the number of these adverse events (Zhou et al. 2022). This evidence concerns the gene TP53 and atherosclerosis.